Currently, the standard of care for patients with glioblastoma multiforme (GBM) consists of surgical resection or biopsy followed by adjuvant concurrent chemo-radiotherapy (CCRT) with temozolomide.¹ To further improve the clinical course of GBM patients, tumor-treating fields (TTFields) were introduced as a concurrent antimitotic treatment to CCRT and had demonstrated significant survival benefit among GBM patients in the EF-14 study.¹ Importantly, a subgroup analysis of the EF-14 study among Asian patients demonstrated that TTFields had significantly improved the 1-year survival rate of GBM patients to 96% when compared to 73% in those receiving temozolomide only (p=0.033).² In a recent interview with Omnihealth Practice, Dr. Woo Yat Ming, Peter, Associate Consultant, Department of Neurosurgery, Kwong Wah Hospital, discussed the clinical application of TTFields in Hong Kong population and reviewed the safety and efficacy of the novel treatment strategy in the local setting.